Arsia, Eagle deal

Eagle will acquire drug formulation and delivery company Arsia for $30 million, including $27.3 million in cash and $2.7 million in Eagle stock. Arsia is also eligible for up to $48 million in milestones.

Arsia's technology is designed to allow subcutaneous administration of high-dose biologics. The technology comprises a library of excipients that disrupt interactions between protein molecules without interfering with the proteins themselves and reduce viscosity of the biologics...